RUNX1 mutation
|
MDS
|
RUNX1 mutation
|
MDS
|
ruxolitinib Sensitive: A2 - Guideline
|
ruxolitinib Sensitive: A2 - Guideline
|
RUNX1 mutation
|
AML
|
RUNX1 mutation
|
AML
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
RUNX1 mutation
|
CMML
|
RUNX1 mutation
|
CMML
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
RUNX1 mutation
|
MDS
|
RUNX1 mutation
|
MDS
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
venetoclax Sensitive: C2 – Inclusion Criteria
|
RUNX1 mutation
|
MDS
|
RUNX1 mutation
|
MDS
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
RUNX1 mutation
|
AML
|
RUNX1 mutation
|
AML
|
venetoclax + RO5503781 Sensitive: C3 – Early Trials
|
venetoclax + RO5503781 Sensitive: C3 – Early Trials
|
RUNX1 mutation
|
AML
|
RUNX1 mutation
|
AML
|
LY3009120 Resistant: C3 – Early Trials
|
LY3009120 Resistant: C3 – Early Trials
|
RUNX1 mutation
|
AML
|
RUNX1 mutation
|
AML
|
cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials
|
cytarabine / daunorubicin liposomal formulation Resistant: C3 – Early Trials
|
RUNX1 mutation
|
AML
|
RUNX1 mutation
|
AML
|
cytarabine Resistant: C3 – Early Trials
|
cytarabine Resistant: C3 – Early Trials
|
RUNX1 mutation
|
MDS
|
RUNX1 mutation
|
MDS
|
azacitidine Resistant: C3 – Early Trials
|
azacitidine Resistant: C3 – Early Trials
|
RUNX1 mutation
|
AML
|
RUNX1 mutation
|
AML
|
cytarabine + clofarabine Sensitive: C3 – Early Trials
|
cytarabine + clofarabine Sensitive: C3 – Early Trials
|
RUNX1 mutation
|
AML
|
RUNX1 mutation
|
AML
|
cytarabine + cladribine Sensitive: C3 – Early Trials
|
cytarabine + cladribine Sensitive: C3 – Early Trials
|
RUNX1 mutation
|
AML
|
RUNX1 mutation
|
AML
|
decitabine + clofarabine Sensitive: C3 – Early Trials
|
decitabine + clofarabine Sensitive: C3 – Early Trials
|
RUNX1 mutation
|
AML
|
RUNX1 mutation
|
AML
|
decitabine + cladribine Sensitive: C3 – Early Trials
|
decitabine + cladribine Sensitive: C3 – Early Trials
|
RUNX1 mutation
|
AML
|
RUNX1 mutation
|
AML
|
CDIAG Sensitive: C3 – Early Trials
|
CDIAG Sensitive: C3 – Early Trials
|
RUNX1 mutation
|
CML
|
RUNX1 mutation
|
CML
|
Tyrosine kinase inhibitor Resistant: C3 – Early Trials
|
Tyrosine kinase inhibitor Resistant: C3 – Early Trials
|
RUNX1 mutation
|
AML
|
RUNX1 mutation
|
AML
|
BTX-A51 Sensitive: C3 – Early Trials
|
BTX-A51 Sensitive: C3 – Early Trials
|
RUNX1 mutation
|
MDS
|
RUNX1 mutation
|
MDS
|
sintilimab Sensitive: C3 – Early Trials
|
sintilimab Sensitive: C3 – Early Trials
|
RUNX1 mutation
|
AML
|
RUNX1 mutation
|
AML
|
tagraxofusp Sensitive: D – Preclinical
|
tagraxofusp Sensitive: D – Preclinical
|